cinobufagin and Mouth-Neoplasms

Anoctamin1 (ANO1), a calcium-activated chloride channel, is frequently overexpressed in several cancers, including oral squamous cell carcinoma (OSCC). OSCC is a highly aggressive cancer and the most common oral malignancy. ANO1 has been proposed as a potential candidate for targeted anticancer therapy. In this study, we performed a cell-based screening to identify novel regulators leading to the downregulation of ANO1, and discovered cinobufagin, which downregulated ANO1 expression in oral squamous cell carcinoma CAL-27 cells. ANO1 protein levels were significantly reduced by cinobufagin in a dose-dependent manner with an IC

Topics: Animals; Anoctamin-1; Antineoplastic Agents; Bufanolides; Carcinoma, Squamous Cell; Cell Proliferation; Down-Regulation; Drug Screening Assays, Antitumor; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Inbred C57BL; Mouth Neoplasms; Neoplasm Proteins; Tumor Cells, Cultured